Format

Send to

Choose Destination
Clin Infect Dis. 2004 Feb 1;38(3):448-51. Epub 2004 Jan 12.

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Author information

1
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia. patrick.charles@mh.org.au

Abstract

We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n=53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n = 5, 9.4%) with those due to vancomycin-susceptible MRSA (n=48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.

PMID:
14727222
DOI:
10.1086/381093
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center